News

MHRA issues post-transition orphan medicine guidance

The Medicines and Healthcare product Regulatory Agency (MHRA) explains that it will provide incentives to encourage the development of products to treat rare diseases, including market exclusivity, refunds for marketing authorisation fees and scientific advice fee waivers for UK-based small and medium enterprises (SME). Read more “MHRA issues post-transition orphan medicine guidance”